Issues related to the impact of the bio-pharmaceutical industry on the economy.
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Issues related to the development of new medical therapies.
Issues related to policy changes to Medicare Part B & D.
Issues related to intellectual property protections in foreign trade agreements.
Duration: April 14, 2009
to
January 31, 2012
General Issues: Economics/Economic Development , Medical/Disease Research/Clinical Labs , Science/Technology , Medicare/Medicaid , Trade (Domestic & Foreign) , Copyright/Patent/Trademark
Spending: about $360,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate, U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steve McBee Legislative Aide, Congressman Norm Dicks
Legislative Aide, Congresswoman Maria Cantwell
Legislative Aide, Congressman Al Swift
Rick Desimone Chief of Staff, Senator Patty Murray
GSA, Special Asst to Regional Administrator, Region 10
GSA, Special Asst to Reg. Administrator, Reg. 10
Jeff Markey L.D./Deputy COS, Representative Doc Hastings
Legislative Director, Representative Jack Metcalf
Graduate Fellow, US Department of State
Intern, Senator John Seymour
Glynda Becker Associate Political Director, White House
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2012
MCBEE STRATEGIC CONSULTING, LLC. terminated an engagement in which they represented PhRMA (on behalf of We Work For Health) on April 20, 2012.
Original Filing: 300474065.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to policy changes to Medicare Part B & D.
Lobbying Issues
Issues related to intellectual property protections in foreign trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2011
In Q4, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300451397.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to policy changes to Medicare Part B & D.
Lobbying Issues
Issues related to intellectual property protections in foreign trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2011
In Q3, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300429716.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform legislation (H.R.1249 & S.23).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property protections in foreign trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2011
In Q2, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300402927.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform legislation (H.R.1249 & S.23).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property protections in foreign trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2011
In Q1, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $40,000. The report was filed on April 20, 2011.
Original Filing: 300377465.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform legislation (S.23, America Invents Act).
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $30,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351351.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $30,000. The report was filed on Oct. 20, 2010.
Original Filing: 300327540.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $10,000. The report was filed on July 20, 2010.
Original Filing: 300302377.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $30,000. The report was filed on April 20, 2010.
Original Filing: 300270257.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries.
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Lobbying Issues
America's Healthy Future Act of 2009- issues related to Medicare Part D.
4th Quarter, 2009
In Q4, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $30,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246297.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies. H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R.1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
America's Healthy Future Act of 2009- issues related to Medicare Part D.
3rd Quarter, 2009
In Q3, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $20,000. The report was filed on Oct. 20, 2009.
Original Filing: 300220461.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
America's Healthy Future Act of 2009 -issues related to Medicare Part D.
2nd Quarter, 2009
In Q2, MCBEE STRATEGIC CONSULTING, LLC. lobbied for PhRMA (on behalf of We Work For Health) , earning $10,000. The report was filed on July 20, 2009.
Original Filing: 300193586.xml
Lobbying Issues
Issues related to the impact of the bio-pharmaceutical industry on the economy of Washington State. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to access to medicines and other medical therapies, the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the development of new medical therapies. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
McBee Strategic Consulting, LLC filed a lobbying registration on May 27, 2009 to represent PhRMA (on belaf of We Work For Health), effective April 14, 2009.
Original Filing: 300170215.xml
Issue(s) they said they’d lobby about: Innovation in the bio-pharmaceutical marketplace AND economic impact of bio-pharmaceutical industry on local communities. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...